Cargando…

STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer

BACKGROUND: Peritoneal carcinomatosis is a fatal clinical presentation of colon cancer, characterized by unresponsiveness to conventional anticancer therapies, including immune checkpoint inhibitors. Here, we elucidated the immune-evasion mechanisms during the peritoneal carcinomatosis of colon canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Seung Joon, Yang, Hannah, Kim, Woo Ram, Lee, Yu Seong, Lee, Won Suk, Kong, So Jung, Lee, Hye Jin, Kim, Jeong Hun, Cheon, Jaekyung, Kang, Beodeul, Chon, Hong Jae, Kim, Chan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Oncolytic and Local Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215239/ https://www.ncbi.nlm.nih.gov/pubmed/34145029 http://dx.doi.org/10.1136/jitc-2020-002195

Ejemplares similares

Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer
por: Lee, Yu Seong, et al.
Publicado: (2020)

Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis
por: Bella, Ángela, et al.
Publicado: (2023)

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
por: Lee, Won Suk, et al.
Publicado: (2022)

Recombinant Mycobacterium smegmatis delivering a fusion protein of human macrophage migration inhibitory factor (MIF) and IL-7 exerts an anticancer effect by inducing an immune response against MIF in a tumor-bearing mouse model
por: Jeong, Hyein, et al.
Publicado: (2021)

Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer
por: Shakfa, Noor, et al.
Publicado: (2023)

Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation
por: Alshebremi, Mohammad, et al.
Publicado: (2023)

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
por: Jiang, Xiaoyi, et al.
Publicado: (2022)

Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases
por: Yang, Annie, et al.
Publicado: (2023)

Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma
por: Wang-Bishop, Lihong, et al.
Publicado: (2020)

High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege
por: Ager, Casey R, et al.
Publicado: (2021)

Ectopic expression of cGAS in Salmonella typhimurium enhances STING-mediated IFN-β response in human macrophages and dendritic cells
por: Waanders, Lisette, et al.
Publicado: (2023)

STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
por: Nakamura, Takashi, et al.
Publicado: (2021)

Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy
por: Alvarez, Maite, et al.
Publicado: (2021)

PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8(+) T cell-dependent antitumor immunity and abscopal effect after local irradiation
por: Yoon, Yi Na, et al.
Publicado: (2022)

Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies
por: Lee, Namhee, et al.
Publicado: (2023)

Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy
por: Muñoz, Nina M., et al.
Publicado: (2021)

Live attenuated bacterium limits cancer resistance to CAR-T therapy by remodeling the tumor microenvironment
por: Guo, Fengguang, et al.
Publicado: (2022)

Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2020)

Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity
por: Yu, Xiaofei, et al.
Publicado: (2021)

Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry
por: Nguyen, Teresa T, et al.
Publicado: (2022)

Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments
por: Bhatta, Maulasri, et al.
Publicado: (2021)

Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity
por: Seclì, Laura, et al.
Publicado: (2023)

Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma
por: Beasley, Georgia M, et al.
Publicado: (2022)

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment
por: Ponce, Santiago, et al.
Publicado: (2023)

CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model
por: Wang, Ruikun, et al.
Publicado: (2022)

Oncolytic vesicular stomatitis virus–based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8(+) T-cell functionality
por: Niavarani, Seyedeh-Raheleh, et al.
Publicado: (2020)

Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy
por: Yang, Zaofeng, et al.
Publicado: (2022)

Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
por: Jung, Bo-Kyeong, et al.
Publicado: (2020)

BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma
por: Kremenovic, Mirela, et al.
Publicado: (2022)

Nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination
por: Huang, Chung-Hsiung, et al.
Publicado: (2020)

Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)
por: Fakih, Marwan, et al.
Publicado: (2023)

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
por: Peluso, Marisa O, et al.
Publicado: (2020)

Nasal administration of recombinant Neospora caninum secreting IL-15/IL-15Rα inhibits metastatic melanoma development in lung
por: Battistoni, Arthur, et al.
Publicado: (2023)

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
por: Hamdan, Firas, et al.
Publicado: (2021)

Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study
por: Curti, Brendan D, et al.
Publicado: (2022)

Neospora caninum: a new class of biopharmaceuticals in the therapeutic arsenal against cancer
por: Lantier, Louis, et al.
Publicado: (2020)

Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression
por: Hwang, Bin-Jin, et al.
Publicado: (2022)

Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming
por: Aleynick, Mark, et al.
Publicado: (2023)

Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy
por: Ghonime, Mohammed G, et al.
Publicado: (2021)

Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
por: Crespo-Rodriguez, Eva, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1m0sp63o6nk7mloh97ksdejd7v